Nomogram predicts bladder stone risk in BPH patients after prostate resection
This retrospective cohort study (2023–2025) developed and validated a nomogram to predict bladder stone risk in 446 patients with benign prostatic hyperplasia (BPH) who underwent transurethral resection of the prostate. The model was trained on 70% of the sample and validated on the remaining 30%.
The nomogram demonstrated excellent discrimination, with an AUC of 0.865 in the training set and 0.882 in the validation set. Among the cohort, 106 patients had bladder stones and 340 did not. Calibration was good, with a Hosmer-Lemeshow test p > 0.05.
Safety and tolerability were not reported. Key limitations include the retrospective, single-center design and the use of only internal validation. The model's performance in external populations is unknown.
The nomogram may serve as a reliable tool for clinicians to guide personalized monitoring and prevention of bladder stones in BPH patients, but it does not establish causation. Practice relevance is limited to risk stratification within this specific cohort.